secwatch.observer — SEC 8-K summary
======================================

Issuer:     SUTRO BIOPHARMA, INC. (STRO)
CIK:        0001382101
Form:       8-K
Filed at:   2022-11-08T23:59:59+00:00
Accession:  0000950170-22-023274
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Sutro BioPharma Q3 revenue $25.1M, cash $287.3M; STRO-002 data at ASH, Phase 2 design by year end
--------------------------------------------------------------------------------

- Revenue $25.1M (up from $8.5M YoY); total operating expenses $46.4M.
- Cash, equivalents and marketable securities $287.3M as of Sep 30, 2022; projected runway into first half 2024.
- STRO-002 oral presentation at ASH 2022 for pediatric AML; Phase 1 ovarian data and Phase 2 design expected by end 2022.
- Vaxcyte positive Phase 1/2 data for VAX-24; Sutro to receive 4% royalties on worldwide net sales.
- Astellas collaboration with $90M upfront received; Merck $10M milestone triggered.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1382101/000095017022023274/0000950170-22-023274-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1382101/000095017022023274/stro-20221108.htm
  HTML page:      https://secwatch.observer/filing/0000950170-22-023274

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer